問卷

TPIDB > Search Result

Search Result

篩選

List

25Cases

2025-04-01 - 2030-06-18

Phase III

Active
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Injectables Injectables Injectables

Participate Sites
8Sites

Recruiting8Sites

2021-06-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-11-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-11-06 - 2023-12-26

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2020-09-01 - 2024-07-05

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-07-01 - 2026-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-09-01 - 2027-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting14Sites

2022-01-01 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

1 2 3